Designing smarter cancer prevention trials.
Summary of "Designing smarter cancer prevention trials."
No Summary Available
Affiliation
Journal Details
This article was published in the following journal.
Name: Nature
ISSN: 1476-4687
Pages: S20-1
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21430717
- DOI: http://dx.doi.org/10.1038/471S20a
Medical and Biotech [MESH] Definitions
American Cancer Society
A voluntary organization concerned with the prevention and treatment of cancer through education and research.
Monitoring, Immunologic
Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumor antigen and other markers (often by RADIOIMMUNOASSAY), studies of cellular or humoral immunity in cancer etiology, IMMUNOTHERAPY trials, etc.
National Cancer Institute (u.s.)
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
Primary Prevention
Specific practices for the prevention of disease or mental disorders in susceptible individuals or populations. These include HEALTH PROMOTION, including mental health; protective procedures, such as COMMUNICABLE DISEASE CONTROL; and monitoring and regulation of ENVIRONMENTAL POLLUTANTS. Primary prevention is to be distinguished from SECONDARY PREVENTION and TERTIARY PREVENTION.
Secondary Prevention
The prevention of recurrences or exacerbations of a disease that already has been diagnosed. This also includes prevention of complications or after-effects of a drug or surgical procedure.
PubMed Articles
Screening smarter, not harder, for prostate cancer.
Biomarkers as surrogate endpoints in cancer trials.
To define and discuss surrogate endpoint biomarkers, which are used in therapeutic trials as a substitute for the clinically meaningful "true" endpoint; and hence, may be used in answering cancer prev...
ABSTRACT: The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challen...
Improved Outcomes in the Malnourished Patient: We're Not There Yet.
Low molecular weight heparins in the treatment of lung cancer.
Introduction: Lung cancer is the major cause of cancer-related death. Venous thromboembolic events (VTEs) occur frequently in lung cancer and are a poor prognostic marker. For prevention and treatmen...
Clinical Trials
Laser Acupuncture for Pain Prevention in Neonates
Pain prevention and/or therapy in neonates is still a challenge. It is widely accepted that early pain experience can have a tremendous impact on the pain memory. We want to investigate if...
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers...
1. To identify reasons for low patient recruitment numbers to clinical trials in a cancer research center setting (and a community setting) in order to attempt to increase accrua...
Observational Cohort Study of Sodium, Weight and CVD
To investigate cardiovascular events among individuals with low sodium intake or large weight changes in a prospective observational follow-up of subjects from the Trials of Hypertension P...
Patients who are intolerant of statins in routine practice, but who lack objective evidence of significant harm, will be randomized to receive statins by either n of 1 trials or standard p...
